First City Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

First City Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-220	Closed	-$733	–	634
2016 Q1	$733	Sell	220 -20	-8%	-$62	﹤0.01%	632
2015 Q4	$850	Hold	240	–	–	﹤0.01%	632
2015 Q3	$1.21K	Hold	240	–	–	﹤0.01%	588
2015 Q2	$1.54K	Hold	240	–	–	﹤0.01%	558
2015 Q1	$1.69K	Hold	240	–	–	﹤0.01%	529
2014 Q4	$1.85K	Hold	240	–	–	﹤0.01%	547
2014 Q3	$1.79K	Hold	240	–	–	﹤0.01%	542
2014 Q2	$2.32K	Hold	240	–	–	﹤0.01%	545
2014 Q1	$1.99K	Buy	+240	New	+$2.06K	﹤0.01%	540

Other funds holding PDLI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

First City Capital Management's PDLI Position: Q2 2016 in Review

First City Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2016, closing a stake of 220 shares — an estimated $733 sold.

First City Capital Management first reported a position in PDLI in Q1 2014 and held it in 9 quarters. The position peaked at $2.32K in Q2 2014. 201 funds tracked by Wall St. Rank hold PDLI as of Q2 2016.

First City Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2016 after selling out during the quarter.
First City Capital Management sold 220 PDL BioPharma, Inc. shares in Q2 2016, an estimated $733.
First City Capital Management first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 9 quarters.
First City Capital Management's PDL BioPharma, Inc. position peaked at $2.32K in Q2 2014.
201 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2016.

Based on First City Capital Management's 13F filing for Q2 2016, filed 16 Aug 2016.